Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

Table 3 Treatment characteristics in six-time intervals

Parameter	2015-2016	2017	2018	2019	2020	2021
Number of patients	1199	827	573	438	199	341
History of previous therapy
Treatment-naïve	543 (45.3)	532 (64.3)	470 (82.0)	385 (87.9)	171 (86)	318 (93.2)
Nonresponder	290 (24.2)	103 (12.5)	23 (4.0)	7 (1.6)	6 (3)	11 (3.2)
Relapser	173 (14.4)	72 (8.7)	49 (8.5)	35 (8)	17 (8.5)	6 (1.8)
Discontinuation due to safety reason	71 (5.9)	40 (4.8)	14 (2.5)	4 (0.9)	1 (0.5)	3 (0.9)
Unknown type of response	120 (10.0)	76 (9.2)	14 (2.5)	7 (1.6)	2 (1)	3 (0.9)
No data	2 (0.2)	4 (0.5)	3 (0.5)	0	2 (1)	0
Number of patients with treatment failure	n = 654	n = 291	n = 100	n = 53	n = 26	n = 23
IFN ± RBV	64 (9.8)	36 (12.4)	2 (2)	0	0	0
PegIFN ± RBV	390 (59.6)	197 (67.7)	48 (48)	14 (26.4)	9 (34.6)	9 (39.1)
PegIFN + RBV + DAA	196 (30)	47 (16.1)	10 (10)	3 (5.7)	0	0
IFN-free	4 (0.6)	11 (3.8)	39 (39)	35 (66)	17 (65.4)	14 (60.9)
No data	0	0	1 (1)	1 (1.9)	0	0
Current treatment regimen
Genotype-specific treatment regimens
ASV + DCV	42 (3.5)	13 (1.6)	0	0	0	0
LDV/(SOF ± RBV)	350 (29.2)	283 (34.2)	154 (26.9)	16 (3.7)	5 (2.5)	4 (1.2)
OBV/PTV/(r ± DSV ± RBV)	745 (62.1)	327 (39.5)	32 (5.6)	0	0	1 (0.3)
GZR/(EBR ± RBV)	0	97 (11.7)	205 (35.8)	76 (17.3)	16 (8)	15 (4.4)
Other	62 (5.2)	104 (12.6)	19 (3.3)	0	0	0
SOF ± SMV ± DCV ± RBV, SMV ± DCV ± RBV
Pangenotypic regimens
GLE/PIB	0	1 (0.1)	59 (10.3)	178 (40.6)	99 (49.8)	117 (34.3)
GLE/(PIB + SOF + RBV)	0	0	0	2 (0.5)	0	0
SOF/(VEL ± RBV)	0	2 (0.3)	104 (18.1)	166 (37.9)	79 (39.7)	195 (57.2)
VOX/VEL/SOF	0	0	0	0	0	9 (2.6)
Current-RBV-containing therapies	855 (71.3)	360 (43.5)	163 (28.4)	44 (10)	12 (6)	23 (6.7)

IFN: Interferon; RBV: Ribavirin; PegIFN: Pegylated interferon; DAA: Direct-acting antivirals; ASV: Asunaprevir; DCV: Daclatasvir; LDV: Ledipasvir; SOF: Sofosbuvir; OBV: Ombitasvir; PTV/r: Paritaprevir; DSV: Dasabuvir; GZR: Grazoprevir; EBR: Elbasvir; SMV: Simeprevir; GLE: Glecaprevir; PIB: Pibrentasvir; VEL: Velpatasvir; VOX: Voxilaprevir.